BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device

    LAVAL, QC, Feb. 2 /CNW/ - BioSyntech, Inc. (TSX: BSY), a biotechnology
company developing biotherapeutic thermogels for regenerative medicine, today
announced that it has completed enrolment for the Canadian-European pivotal
trial of its cartilage repair device, BST-CarGel(R). The Company achieved its
planned objective of enrolling 80 patients into the randomized trial.
    "We are grateful to the distinguished group of orthopaedic surgeons who
participated in this trial and were instrumental in achieving this milestone,
despite the challenges presented by our strict eligibility criteria," said
Michel Lagueux, Chairman of the Board of Directors. "With enrolment now
complete, we look forward to the final results from this pivotal trial, which
will be available in the first quarter of 2010 and will support marketing
applications for BST-CarGel(R) in Canada and Europe. We also continue to
advance the IDE (Investigational Device Exemption) application process with
the US FDA, for BST-CarGel(R) in the US."
    This randomized trial compares the treatment of cartilage lesions using
BST-CarGel(R) applied following microfracture to treatment with microfracture
alone. The trial enrolled subjects aged 18 to 55 years of age with focal
cartilage lesions less than 10 cm(2) located on the femoral condyles of the
knee. Subjects are further stratified by their lesion type, either
characterized as acute (i.e. traumatic) or chronic (i.e. degenerative). The
primary endpoint for this trial is cartilage repair at twelve months, defined
by the quantity and quality of the repaired tissue as measured with
quantitative magnetic resonance imaging (MRI). Secondary endpoints are safety
and knee-related pain, stiffness and function as measured using the Western
Ontario and McMaster Universities (WOMAC) osteoarthritis index questionnaire.

    About BioSyntech

    BioSyntech is a medical device company specialized in the development,
manufacturing and commercialization of advanced biotherapeutic thermogels for
regenerative medicine (tissue repair) and therapeutic delivery. BioSyntech's
platform technology is a family of hydrogels called BST-Gel(R), some of which
are liquid at low temperature and solid at human body temperature. These gels
can be injected or applied to a specific local site and offer beneficial
properties for the local repair of damaged tissue such as cartilage, bone and
chronic wounds and provide the benefit of avoiding invasive surgery. For
additional information, visit

    Forward-Looking Statements

    This press release contains forward-looking statements and information
which are subject to material risks and uncertainties. Such statements are not
historical facts and are based on the current expectations of management. You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause actual results, future circumstances, or events
to differ materially from those projected in the forward-looking information.
These risks include, but are not limited to, those associated with our
capacity to finance our activities, the adequacy, timing, and results of our
clinical trials, the regulatory approval process, competition, securing and
maintaining corporate alliances, market acceptance of the Company's products,
the availability of government and insurance reimbursements for the Company's
products, the strength of intellectual property, the success of research and
development programs, reliance on subcontractors and key personnel, and other
risks and uncertainties detailed from time-to-time in our filings with the
Canadian securities commissions.
    Readers should not place undue reliance on the forward-looking
information, given that (i) our actual results could differ materially from a
conclusion, forecast or projection in the forward-looking information, and
(ii) certain material factors or assumptions which were applied in drawing a
conclusion or making a forecast or projection as reflected in the
forward-looking information, could prove to be inaccurate. Additional
information about (i) the material factors that could cause actual results to
differ materially from the conclusion, forecast or projection in the
forward-looking information, and (ii) the material factors or assumptions that
were applied in drawing a conclusion or making a forecast or projection as
reflected in the forward-looking information, is contained in the Company's
annual report and other documents filed from time to time with the Canadian
securities commissions which are available at These statements
speak only as of the date they are made, and we assume no obligation to revise
such statements as a result of any event, circumstance or otherwise, except in
accordance with law.

    %SEDAR: 00020217EF

For further information:

For further information: James Smith, The Equicom Group, (416) 815-0700

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890